Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Isfahan Ophthalmology Research Center |
---|---|
Information provided by: | Isfahan Ophthalmology Research Center |
ClinicalTrials.gov Identifier: | NCT00703235 |
Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema. This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.
Condition | Intervention | Phase |
---|---|---|
Macular Edema Diabetic Retinopathy |
Drug: Bevacizumab |
Phase II Phase III |
Study Type: | Interventional |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | MUI - clinical - 185290 |
Study First Received: | June 20, 2008 |
Last Updated: | June 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00703235 History of Changes |
Health Authority: | Iran: Ministry of Health |
Eye Diseases Vascular Diseases Diabetes Mellitus Edema Endocrine System Diseases Macular Degeneration Retinal Degeneration Bevacizumab |
Angiogenesis Inhibitors Diabetic Angiopathies Macular Edema Signs and Symptoms Diabetic Retinopathy Endocrinopathy Retinal Diseases Diabetes Complications |
Antineoplastic Agents Growth Substances Eye Diseases Physiological Effects of Drugs Vascular Diseases Diabetes Mellitus Retinal Degeneration Edema Endocrine System Diseases Macular Degeneration Bevacizumab Angiogenesis Inhibitors |
Pharmacologic Actions Diabetic Angiopathies Macular Edema Signs and Symptoms Diabetic Retinopathy Therapeutic Uses Cardiovascular Diseases Growth Inhibitors Angiogenesis Modulating Agents Retinal Diseases Diabetes Complications |